Brokers Set Expectations for DexCom Inc.’s Q3 2016 Earnings (DXCM)
DexCom Inc. (NASDAQ:DXCM) – Stock analysts at B. Riley issued their Q3 2016 earnings per share estimates for DexCom in a research note issued to investors on Tuesday. B. Riley analyst G. Chodaczek expects that the brokerage will earn ($0.15) per share for the quarter. B. Riley currently has a “Neutral” rating and a $97.00 target price on the stock. B. Riley also issued estimates for DexCom’s Q4 2016 earnings at $0.02 EPS, FY2016 earnings at ($0.61) EPS, Q1 2017 earnings at ($0.08) EPS, Q2 2017 earnings at $0.01 EPS, Q3 2017 earnings at $0.07 EPS, Q4 2017 earnings at $0.21 EPS and FY2017 earnings at $0.21 EPS.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.12. The firm had revenue of $137.30 million for the quarter, compared to analysts’ expectations of $132.48 million. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. DexCom’s revenue was up 47.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.05) earnings per share.
Other equities analysts have also recently issued research reports about the company. Jefferies Group restated a “buy” rating and set a $98.00 price objective on shares of DexCom in a report on Wednesday, August 3rd. Benchmark Co. dropped their price objective on DexCom from $106.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, August 3rd. Deutsche Bank AG boosted their price objective on DexCom from $90.00 to $98.00 and gave the company a “buy” rating in a report on Friday, July 15th. Canaccord Genuity restated a “buy” rating and set a $95.00 price objective on shares of DexCom in a report on Wednesday, July 13th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of DexCom in a report on Monday, June 20th. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $95.08.
DexCom (NASDAQ:DXCM) opened at 87.66 on Thursday. DexCom has a 12-month low of $47.92 and a 12-month high of $96.38. The firm’s 50-day moving average is $91.93 and its 200-day moving average is $77.09. The stock’s market capitalization is $7.35 billion.
In other news, EVP Andrew K. Balo sold 5,000 shares of the stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $80.12, for a total value of $400,600.00. Following the transaction, the executive vice president now directly owns 134,979 shares of the company’s stock, valued at $10,814,517.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jorge A. Valdes sold 32,000 shares of the stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $79.36, for a total value of $2,539,520.00. Following the completion of the transaction, the insider now directly owns 123,667 shares in the company, valued at $9,814,213.12. The disclosure for this sale can be found here. Corporate insiders own 2.80% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in DXCM. AXA raised its position in shares of DexCom by 2.5% in the first quarter. AXA now owns 524,721 shares of the medical device company’s stock worth $35,634,000 after buying an additional 12,791 shares in the last quarter. State Street Corp raised its position in shares of DexCom by 7.2% in the first quarter. State Street Corp now owns 1,055,774 shares of the medical device company’s stock worth $71,699,000 after buying an additional 71,009 shares in the last quarter. Cupps Capital Management LLC raised its position in shares of DexCom by 20.9% in the first quarter. Cupps Capital Management LLC now owns 43,464 shares of the medical device company’s stock worth $2,951,000 after buying an additional 7,518 shares in the last quarter. Menta Capital LLC purchased a new position in shares of DexCom during the first quarter worth $679,000. Finally, BlackRock Fund Advisors raised its position in shares of DexCom by 0.6% in the first quarter. BlackRock Fund Advisors now owns 929,897 shares of the medical device company’s stock worth $63,149,000 after buying an additional 5,443 shares in the last quarter. 99.37% of the stock is currently owned by institutional investors and hedge funds.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.